Status:
COMPLETED
Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder
Lead Sponsor:
Pfizer
Conditions:
Hypercholesterolemia, Familial
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To evaluate the efficacy and safety of the lipid drug Torcetrapib/atorvastatin in patients with genetically known di...
Detailed Description
For additional information please call: 1-800-718-1021
Eligibility Criteria
Inclusion
- Diagnosis of Homozygous Familial Hypercholesterolemia
Exclusion
- Women who are pregnant or lactating, or planning to become pregnant.
- Subjects with a clinically indicated need for statin (HMG-CoA reductase inhibitor) therapy other than atorvastatin or other concomitant therapy with known lipid altering effects on LDL-C and HDL-C including fibrates and nicotinic acid
- Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors
- Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluationof response, or render unlikely that the subject would complete the study
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
End Date :
November 1 2005
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00134511
Start Date
March 1 2005
End Date
November 1 2005
Last Update
November 7 2007
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Boston, Massachusetts, United States, 02114
2
Pfizer Investigational Site
Chicoutimi, Quebec, Canada, G7H 5H6
3
Pfizer Investigational Site
Ste-Foy, Quebec, Canada, G1V 4M6
4
Pfizer Investigational Site
Parktown, Johannesburg, South Africa, 2193